Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cluster of differentiation 44 (CD44) is a type I transmembrane glycoprotein that serves as the primary cell-surface receptor for hyaluronic acid (HA). In the ocular surface, it is highly expressed in the basal layers of the corneal and conjunctival epithelium, where it plays a critical role in cell-cell and cell-matrix interactions. CD44 is essential for corneal wound healing, as its interaction with HA promotes the migration of epithelial cells to close defects and facilitates re-epithelialization. It is also involved in inflammatory responses and the maintenance of the limbal stem cell niche. Therapeutically, CD44 is targeted by HA-containing ophthalmic solutions to treat dry eye and promote wound closure, and it is being explored as a docking site for targeted drug delivery using HA-coated nanoparticles.
Binding of hyaluronic acid to the CD44 receptor on corneal and conjunctival epithelial cells promotes cell migration, adhesion, and proliferation, which are essential for maintaining the ocular surface integrity and accelerating wound healing.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cluster of differentiation 44 (CD44).